

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 7, 2021

OraSure Technologies, Inc.  
(Exact Name of Registrant as Specified in Charter)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

001-16537  
(Commission  
File Number)

36-4370966  
(I.R.S. Employer  
Identification No.)

220 East First Street  
Bethlehem, Pennsylvania  
(Address of Principal Executive Offices)

18015-1360  
(Zip Code)

Registrant's telephone number, including area code: 610-882-1820

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.000001 par value per share	OSUR	The NASDAQ Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by a check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

**Increase in the Number of Directors on the Board of Directors and New Director Appointments**

On November 7, 2021, the Board of Directors (the “Board”) of OraSure Technologies, Inc. (the “Company”) increased the number of directors who may serve on the Board from nine to ten pursuant to authority granted in the Company’s Certificate of Incorporation.

In addition, on November 7, 2021 the Board appointed Nancy J. Gagliano, M.D. and Anne C. Whitaker as new members of the Board. Mrs. Whitaker will serve as a Class II Director, with an initial term expiring at the Company’s 2023 Annual Meeting of Stockholders, and as a member of the Board’s Audit Committee. Dr. Gagliano will serve as a Class III Director, with an initial term expiring at the Company’s 2024 Annual Meeting of Stockholders, and as a member of the Board’s Nominating and Corporate Governance Committee.

The Board has determined that Dr. Gagliano and Mrs. Whitaker are each independent under the rules of the NASDAQ Stock Market LLC and meet the independence requirements of Section 10A(m)(3) of the Securities and Exchange Act of 1934, as amended, and the relevant rules promulgated thereunder.

Mrs. Whitaker and Dr. Gagliano will each participate in the Company’s Non-Employee Director Compensation Policy (the “Policy”). A description of the Policy is set forth in the section entitled “Director Compensation,” in the Company’s Definitive Proxy Statement for the 2021 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on April 8, 2021.

Pursuant to the Policy and the Company’s Stock Award Plan, Mrs. Whitaker and Dr. Gagliano were each granted an initial equity award of time-vested restricted shares of the Company’s common stock having an aggregate value of \$105,000. The foregoing grants will vest two years following the date of grant. Vesting will be accelerated in the event of a Change in Control (as such term is defined in the Stock Award Plan). Mrs. Whitaker and Dr. Gagliano will each also receive cash fees and additional annual equity compensation pursuant to the Policy.

There are no arrangements or understandings between either Mrs. Whitaker or Dr. Gagliano and any other person pursuant to which either of them was selected as a director of the Company. Neither Mrs. Whitaker nor Dr. Gagliano has any familial relationship with any member of the Board or executive officer of the Company, and there are no transactions in which either Mrs. Whitaker or Dr. Gagliano has an interest requiring disclosure under Item 404(a) of Regulation S-K.

A press release announcing the appointments of Mrs. Whitaker and Dr. Gagliano to the Board is attached as Exhibit 99.1 to this Report and is incorporated by reference herein.

**Item 9.01 – Financial Statements and Exhibits.**

**(d) Exhibits**

<b>Exhibit Number</b>	<b>Description</b>
99.1	<a href="#">Press Release, dated November 8, 2021, announcing the appointment of Nancy J. Gagliano, M.D. and Anne C. Whitaker to the OraSure Technologies, Inc. Board of Directors.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

**Signatures**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ORASURE TECHNOLOGIES, INC.

Date: November 8, 2021

By: /s/ Jack E. Jerrett

Jack E. Jerrett

Senior Vice President, General Counsel and Secretary

---



OraSure Technologies, Inc.

Investor Contact:  
Scott Gleason  
Interim CFO & SVP Investor Relations & Corp. Communications  
484-425-0588  
sgleason@orasure.com

Media Contact:  
Amy Koch  
Sr. Mgr. Corporate Communications  
484-523-1815  
media@orasure.com

### **OraSure Technologies Appoints Two New Members to the Board of Directors**

***New Appointments Bring to the Company Significant Executive Leadership, Global Product Development, Public Health, and the Retail Pharmacy Market Experience***

**BETHLEHEM, PA., November 8, 2021 (Globe Newswire)** – OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today the appointment Nancy J. Gagliano, M.D. and Anne C. Whitaker to the Company’s Board of Directors, effective November 8, 2021. Dr. Gagliano was a practicing physician in internal medicine, has extensive retail pharmacy leadership experience, and was one of the leaders of the RADx Tech, Rapid Acceleration of Diagnostics program for the National Institute of Health to bring new diagnostic technologies to market to counter the global COVID-19 pandemic. Dr. Gagliano will serve as a Class III Director with an initial term expiring at the Company’s 2024 Annual Meeting of Stockholders. She will also serve on the Nominating and Corporate Governance Committee of the Board. Mrs. Whitaker has held numerous board and executive level positions in the pharmaceutical industry. She has been recognized by Fierce Pharma as one of the top 25 Most Influential Women in BioPharma, PharmaVoice as one of the Top 100 most Inspiring Leaders in Healthcare and Women, Inc. as one of the most Influential Corporate Directors. She is currently the Chairperson of the Board of Directors of Aerami Therapeutics. Mrs. Whitaker will serve as a Class II Director with an initial term expiring at the Company’s 2023 Annual Meeting of Stockholders. She will also serve on the Audit Committee of the Board.

“We are exceptionally privileged to bring two new board members to our team of the caliber and experience of Nancy and Anne,” said Stephen S. Tang, Ph.D., President and Chief Executive Officer of OraSure Technologies. “Their knowledge bases in critical areas such as global product development, public health, and the retail pharmacy market will be critical as we look to drive increased innovation and execute on our long-term global growth strategy.”

Dr. Gagliano, age 62, has over 35 years of experience as a senior healthcare physician executive and practicing physician in internal medicine. Dr. Gagliano most recently served as an executive leader of the National Institute of Health’s RADx Tech, Rapid Acceleration of Diagnostics program. In this position she has helped oversee over one billion dollars of sponsored programs to bring millions of new COVID-19 tests to market. Prior to her work for the National Institute of Health, Dr. Gagliano was the Chief Medical Officer of Culbert Healthcare Solutions, providing strategic guidance on healthcare consulting services. Before

---

joining Culbert Healthcare, Dr. Gagliano spent six years with CVS Health holding senior leadership positions including as the Chief Medical Officer of Minute Clinic, and as a Senior Vice President overseeing key programs such as the enterprise smoking cessation program and the development of the company's telemedicine program. Prior to her leadership roles at CVS Health, Dr. Gagliano was a practicing internal medicine physician and held numerous leadership positions at Massachusetts General Hospital and Massachusetts General Physicians Organization.

Dr. Gagliano holds a M.D. from Harvard Medical School, an MBA from Northeastern University, and a Bachelors of Science Degree from Union College in Computer Science and Biology.

Mrs. Whitaker, age 54, is a seasoned healthcare executive and director with more than 30 years of experience with a proven track record as an executive of building and leading high-performance teams. Mrs. Whitaker currently serves as Managing Partner of Anne Whitaker Group, LLC, a board and private equity advisory firm, and is the current Chairperson of the Board of Aerami Therapeutics, a private life science company. Prior to taking the Chair role at Aerami, Anne served as the CEO from October 2018 to November 2020 and as a director from July 2018. She also serves as an independent director on the boards of three public companies including Faron Pharmaceuticals, a development stage pharma company; Caladrius, a development stage biotech company; and Mallinckrodt, a specialty pharmaceutical company. In addition to her board work, she is an active industry advisor to private equity and venture capital funds in the US and Europe. Mrs. Whitaker started her healthcare career with The Upjohn Company selling pharmaceuticals. She subsequently transitioned to GlaxoSmithKline PLC where she spent 19 years and rose in the commercial ranks from a sales representative to become a Senior Vice President, Business Unit Head for the Cardiovascular, Metabolic, and Urology franchises in 2009. Anne joined Sanofi SA in 2011 as the President of the North America Pharmaceutical Region. Anne served as the CEO and President of Synta Pharmaceuticals, Inc. in 2014 and 2015. She joined Bausch Health as an Executive Vice President and Company Group Chairman for the Branded Pharmaceuticals segment in mid-2015. From February 2017 until April 2018 she served as the CEO and President of Novoclem Therapeutics, Inc.

Mrs. Whitaker holds a Bachelor of Science degree in chemistry from the University of North Alabama.

### **About OraSure Technologies**

OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit [www.orasure.com](http://www.orasure.com).

---

